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The roles of estrogens have been best studied in the breast, breast cancers, and in the
female reproductive tract. However, estrogens have important functions in almost every
tissue in the body. Recent clinical trials such as the Women’s Health Initiative have high-
lighted both the importance of estrogens and how little we know about the molecular
mechanism of estrogens in these other tissues. In this review, we illustrate the diverse
functions of estrogens in the bone, adipose tissue, skin, hair, brain, skeletal muscle and
cardiovascular system, and how the loss of estrogens during aging affects these tissues.
Early transcriptional targets of estrogen are reviewed in each tissue.We also describe the
tissue-speciﬁc effects of selective estrogen receptor modulators (SERMs) used for the
treatment of breast cancers and postmenopausal symptoms.
Keywords: estrogen, SERM, tissue specificity, aging
INTRODUCTION
Estrogens play a role in almost all cells and tissues in the body
(Figure 1). Many of these roles have been observed in women who
have a decrease in estrogens due to menopause or gonadectomy.
Other effects have been observed due to differences in gender, such
as autoimmune disease prevalence in either men or women. We
are only starting to understand the molecular effects of estrogens
in different tissues.
Estrogens signal through two nuclear receptors: estrogen recep-
tor alpha (ERα) and estrogen receptor beta (ERβ). ERα and ERβ
are both expressed in most, if not all, tissues, though usually at
lower levels than those found in reproductive tissues (Zallone,
2006). ERα and ERβ can bind to DNA at speciﬁc DNA motifs
termed estrogen response elements (EREs). The “classical” ERE is
a 13 base pair inverted palindromic sequence – GGTCANNNT-
GACC. In addition, ERα can indirectly activate or repress tran-
scription by binding to otherDNAbinding proteins. Furthermore,
estrogen can have non-genomic effects inducing the phospho-
rylation of components of various signaling pathways (e.g., the
MAPK pathway) or calcium regulation (reviewed in reference
Levin, 2005).
TheWomen’s Health Initiative (WHI) was a large-scale clinical
trial designed to assess the risks and beneﬁts of the use of estrogen
or estrogen plus progestin as part of hormone replacement ther-
apy (HRT) for postmenopausal women. This trial was stopped
after 5 years of data collection due to adverse risks of taking hor-
mone therapy. It was thought that estrogen would protect women
against coronary heart disease, but the opposite was observed. Fur-
thermore, estrogen plus progestin led to an increased number of
invasive breast cancers. In contrast, women taking estrogen plus
progestin had a decreased number of colorectal cancers and hip
fractures. This trial demonstrated the tissue-speciﬁc effects of hor-
mones in postmenopausal women and highlighted the need for a
molecular understanding of estrogens and progestins in different
tissues.
Selective estrogen receptormodulators (SERMs) are ER ligands
that are antagonists in some tissues, but have either partial or full
agonist activity in others. Tamoxifen, a ﬁrst-generation SERM, has
been clinically used for decades to treat ER-positive breast can-
cers. Raloxifene, a second-generation SERM is approved for the
prevention of breast cancer and treatment of osteoporosis. Baze-
doxifene and lasofoxifene are third generation SERMs that are
FDA-approved for the treatment of postmenopausal osteoporo-
sis. Each of these SERMs has a different tissue proﬁle with both
favorable and unfavorable effects (Table 1). Each SERM leads to a
different conformational change in ER after ligand binding, caus-
ing a differential recruitment of coactivators, corepressors, and
other transcriptional factors.
This review will focus on the effects of estrogens and SERMs
in the bone, adipose tissue, skin, hair, brain, skeletal muscle and
cardiovascular system, and how the loss of estrogens during aging
affects these tissues. We will highlight the recent knowledge about
aging effects and their consequences in these tissues and we will
discuss the underlying biological mechanisms in both humans
and experimental animal models. For this review we focus on
direct transcriptional targets deﬁned as genes regulated in 24 h or
less upon E2 treatment because longer hormone treatment could
result in the activationof indirect targets, e.g., inducedby increased
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FIGURE 1 |Tissues and organs affected by estrogen function. Estrogens
play an important role in almost all cells and tissues in the body with
gender-independent and gender-speciﬁc.
differentiation. The role of estrogen receptors (ERs) in cancers
(such as breast cancer and endometrial cancer) is extremely impor-
tant and has been thoroughly reviewed elsewhere (for example, see
Shao and Brown, 2004; Barone et al., 2010; Zwart et al., 2011).
E2 IN BONE AND AGING
In 1940 Fuller Albright described postmenopausal osteoporosis
and proposed that it was due to estrogen deﬁciency (Albright et al.,
1940). During menopause, as estrogen levels decrease sharply,
bone mineral density also decreases. Within the ﬁrst 5 years after
menopause women lose a large amount of trabecular bone, fol-
lowed by a slower loss for the remaining years of life in both
cortical and trabecular bone (Khosla et al., 2011). Treatment of
women with HRT (either estrogen alone or estrogen plus prog-
estin) has been shown to prevent this bone loss (Rossouw et al.,
2002). In 2002 WHI showed that HRT prevents bone fractures
(Rossouw et al., 2002).While we have long known about the bene-
ﬁcial effects of estrogen in bone, the molecular mechanism for the
role of estrogen in bone cells is only beginning to be unraveled.
Postmenopausal loss of estrogens can be mimicked in ovariec-
tomized (OVX)mice and ER knockout mice; each of these models
has a decrease in cortical and cancellous bone mineral density.
The bone phenotypes of ERα knockout (ERαKO), ERβ knockout
(ERβKO), and double knockout (ERαβKO) have been described
(Windahl et al., 2002). Female and male ERα null mice have a
decrease in cortical bone mineral density, whereas ERβKO mice
have normal cortical and cancellous bone mineral density. The
ERαβKO mice have both decreased cortical and decreased can-
cellous bone mineral density, suggesting that ERα and ERβ can
replace each other in cancellous bone, but they also have distinct
roles. Furthermore, ERα has been speciﬁcally deleted in osteo-
clasts using a cathepsin K-cre (Nakamura et al., 2007) and a
lysozyme M-cre (Martin-Millan et al., 2010). Both strains of mice
with osteoclast speciﬁc deletions of ERα have trabecular bone loss,
highlighting the importance of ERα in osteoclasts.
Overall, 17β-estradiol (E2) is protective in bone through its
effects on the immune system, stromal cells, osteoblasts, and osteo-
clasts. Normally, when estrogens are present, osteoclasts undergo
apoptosis, shifting the balance to an overall maintenance or build-
ing of bone. To this end, E2 induces the transcription of FasL
speciﬁcally in osteoblasts, to induce osteoclast apoptosis in a
paracrinemanner (Krum et al., 2008a). Furthermore, loss of estro-
gens leads to an increase in the serum cytokines IL-1, IL-6, IL-7,
and TNFα. These osteoclastogenic cytokines, produced in T-cells,
stromal cells, and osteoblasts, lead to an overall decrease in bone
mineral density and an increase in osteoclast number (Krum
et al., 2010). Estrogens also decrease osteoclastogenesis by sev-
eral additional mechanisms. Estrogens increase osteoprotegerin
(OPG) from osteoblasts (Bord et al., 2003), the decoy receptor
for receptor activator of NF-kappa-B ligand (RANKL), an essen-
tial cytokine for osteoclastogenesis, and decrease the activity of
osteoclasts by decreasing cathepsin K and tartrate-resistant acid
phosphatase (TRAP; Kremer et al., 1995).
Estrogens increase bone mineral density by affecting
osteoblasts. Although the reports on the role of E2 in osteoblast
proliferation and differentiation are confusing (reviewed in Krum,
2011), in vivo loss of E2 leads to an increase in osteoblast apopto-
sis (Kousteni et al., 2002). In the hormone replete state E2 induces
the anti-apoptotic protein Bcl-2 to prevent osteoblast apoptosis
(Pantschenko et al., 2005). Furthermore, E2 leads to activation
of the Src/Shc/ERK pathway that blocks apoptosis (Kousteni et al.,
2001). E2 also increases osteoblast differentiation by up-regulating
bone morphogenic protein 2 (BMP-2; Zhou et al., 2003), which
has been shown to stimulate bone formation in vitro and in vivo.
In the treatment of osteoporosis both HRT and SERMs are
effective. The NSABP Study of Tamoxifen and Raloxifene Trial
(STAR Trial) was conducted to directly compare tamoxifen with
raloxifene in a population of women at increased risk for breast
cancer. One of the endpoints was fracture reduction, and both
tamoxifen and raloxifene treatments resulted in similar numbers
of fractures. The genes regulated by tamoxifen and raloxifene in
bone cells in vivo or in vitro are unknown, as is the reason for
the agonist activity of SERMs in bone. Bazedoxifene and laso-
foxifene are also approved for the treatment of postmenopausal
osteoporosis. In summary, estrogens are protective in bone and
several SERMs are already developed to treat osteoporosis. The
knowledge of the molecular mechanism for the role of estrogen in
bone may contribute to the development of an optimal treatment
for women with a SERM to minimize the negative side effects of
existing SERMs.
E2 IN ADIPOSE TISSUE AND AGING
Adipose tissue distribution is dimorphic in humans (Cooke and
Naaz, 2004). Compared to men, women have more subcuta-
neous fat, which develops in puberty and might be therefore
preferentially promoted by estrogens (Cooke and Naaz, 2004).
Interestingly, the increase of abdominal fat seems to be inhibited
by estrogens in premenopausal women contrary to men who are
prone to depot abdominal fat (Cooke and Naaz, 2004). Though,
when E2 levels decline in postmenopausal women abdominal
fat increases (Cooke and Naaz, 2004). The postmenopausal sta-
tus is therefore typically associated with a gain in body weight,
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especially abdominal obesity, which increases the risk of develop-
ing a metabolic syndrome (reviewed in Carr, 2003; Teede et al.,
2010).
In humans and rodents both ERα and ERβ are expressed in
adipose tissue (Cooke and Naaz, 2004). 17β-estradiol (E2) can
also signal through the yet not well-characterized membrane-
associated ER in adipocytes (Dos Santos et al., 2002). Direct ERα
and ERβ targets in adipocytes are still unknown, although poten-
tial targets are described here. A widely used in vivo model to
investigate age-related changes in female body fat mass is ovariec-
tomy (ovx) of female rodents, which become obese. Importantly,
E2 treatment can reverse the post-ovariectomy-induced weight
gain (Pedersen et al., 1992). ERαKO mice are also used to study
the role of E2 in fat. During the whole life span ERαKO mice
develop more white adipose tissue than wildtype animals, which
is in contrast to normal body weight and adipose tissue of ERβKO
mice (Ohlsson et al., 2000).
In humans leptin appears to be sexually dimorphic due to
higher levels in women when compared to age-matched men
(Rosenbaum et al., 1996; Saad et al., 1997). Leptin/obese knock-
out mice show excessive fat accumulation (Zhang et al., 1994) and
ovariectomy (ovx) of these mice leads to a decrease of adipose tis-
sue (Yoneda et al., 1998; Gui et al., 2004). Interestingly, this effect
was reversible byE2 administration for 24 h (Machinal et al., 1999),
but not after 12 h of E2 treatment (Gui et al., 2004).
The prevalence of the metabolic syndrome is increased in post-
menopausal women relative to premenopausal women (Park et al.,
2003). Studies analyzing adipose tissues from postmenopausal
women demonstrated an increase of markers associated with
insulin sensitivity (e.g., peroxisome proliferator-activated recep-
tor γ; fatty acid transporter), a reduced expression of markers
involved in fat turnover (e.g., acetyl CoA carboxylase a, long chain
acyl CoA dehydrogenase, hormone sensitive lipase), and a reduc-
tion in aromatase (CYP19A1) mRNA levels (Misso et al., 2005a,b).
Genetically manipulated mice with a loss in E2 signaling induced
by Cyp19a1 or ERα deﬁciency are characterized by increased vis-
ceral adiposity, insulin resistance and impaired glucose tolerance,
which among others are features of themetabolic syndrome (Carr,
2003).
Adiponectin (ADIPOQ) belongs to the group of adipose-
derived hormones that are known as adipokines. ADIPOQ may
play a role in themetabolic syndromedue to its inverse relationship
to high fat amounts and increased insulin resistance (Carr, 2003).
Studies on the adiponectin status in humans have shown either
increased or equal levels in postmenopausal women (Nishizawa
et al., 2002). When E2 is depleted in rodents, Adipoq is decreased
in murine adipose tissue (Gui et al., 2004; Misso et al., 2005b).
However, after E2 administration for 12 h no effect on Adipoq
expression was observed (Gui et al., 2004). Interestingly, stud-
ies examining Adipoq expression in adipose tissue of ovx rodents
came to different results because adiponectin was shown to be
either down-regulated in CD1 mice or not changed in Sprague-
Dawley rats (Gui et al., 2004; Fazliana et al., 2009). Therefore,
additional studies must be done to determine if ADIPOQ is a true
E2 target in humans and/or rodents.
Another adipokine, resistin (RETN ), may be also involved
in the development of the metabolic syndrome. Although the
physiological relevance of resistin in obesity and insulin resistance
in humans is controversially discussed (Kusminski et al., 2005),
RETN is E2-dependently regulated in adipose tissue. Studies have
shown that Retn is upregulated in ovx rodents (Gui et al., 2004;
Fazliana et al., 2009) and down-regulated after 24 h E2 treatment
(Huang et al., 2005). However, Retn is not affected after 12 h E2
administration, which implies a time-dependent action of E2 in
the regulation of Retn or potentially that Retn is not a direct ER
target gene (Gui et al., 2004). Studies about adipokines and their
E2-dependent role in obesity or the metabolic syndrome remain
still controversial due to results from a widely used in vitro model
utilizing murine ﬁbroblasts (3T3-L1), which express endogenous
ERα and ERβ and can be differentiated into adipocytes (Student
et al., 1980). Chen et al. (2006) showed that during this differenti-
ation process E2 can lead to a dose- and time-dependent increase
in Retn gene expression. However, Yi et al. (2008) found contrary
results because treatment of 3T3-L1-derived mature adipocytes
with E2 (10−5 to 10−9 M) for 24 h neither affected adipokine gene
expression (e.g., resistin, adiponectin) nor the expression of ERα
andERβ. Furthermore, it was shown that E2 suppresses the expres-
sion of Adipoq only in early-differentiated 3T3-L1 ﬁbroblasts but
not in completely differentiated cells suggesting a time-dependent
E2 activity (Murase et al., 2006).
Glucocorticoids might also play an important role in adi-
pose tissue development and the onset of the metabolic syn-
drome. HSD11B1 (hydroxysteroid 11-beta-dehydrogenase 1) con-
verts inactive cortisone into its active form cortisol, whereas the
other isoform HSD11B2 catalyzes the back reaction. The enzyme
HSD11B1 may play a role in adipose tissue development due to
its increased mRNA levels and activity in most obese humans
(White et al., 2008). The interplay between E2 and HSD11B1 was
also studied by Engeli et al. evaluating the expression of different
HSD11B isoforms in adipose tissue of aged women. Interestingly,
the expression of HDS11B1 was increased, whereas HSD11B2
levels were decreased in centrally obese menopausal women com-
pared to lean menopausal women. These data suggest that E2
might play a role in preventing obesity and the metabolic syn-
drome by controlling the expression of different protein isoforms
(Engeli et al., 2004). In contrast to in vivo data, a 24 h E2 treatment
of primary pre-adipocytes from aged women led to an increase in
HSD11B1 expression (Dieudonne et al., 2006). Furthermore, stud-
ies using mouse models suggest an important role of HSD11B1
in metabolic syndrome. Over-expression of HSD11B1 under the
aP2 promoter resulted in a phenotype very similar to the meta-
bolic syndrome (Masuzaki et al., 2001), whereas mice deﬁcient for
HSD11B1 are protected from this disease (Kotelevtsev et al., 1997;
Morton et al., 2001). The discrepancies about the E2-dependent
down-or up-regulationof HSD11B1 in adipose tissue remain to be
resolved and may contribute to clarify its role in the development
of the metabolic syndrome.
To gain more insight into the mechanisms by which E2 is
involved in the regulation of insulin sensitivity, glucose metab-
olism, body fat accumulation, and the metabolic syndrome,
Macotela et al. (2009) examined the gene expression of glucose
transporters and key lipogenic markers. They found a gender spe-
ciﬁc difference in the glucose and lipid metabolism of adipocytes,
which are characterized by the increased expression of Glut4
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[solute carrier family 2 (facilitated glucose transporter), mem-
ber 4], Glut1, Acc1 (acetyl CoA carboxylase-1), and Fasn (fatty
acid synthase) in female mice (Macotela et al., 2009). Interestingly,
Glut4 and Acc1 are down-regulated in ovx mice and it remains to
be elucidated whether the same gene regulation can be also found
in postmenopausal women that have an increased prevalence to
develop a metabolic syndrome (Park et al., 2003; Macotela et al.,
2009).
As in other tissues, E2 regulates both genomic and non-
genomic signaling in adipocytes. E2 administration in primary rat
adipocytes for as little as 5–15min leads to MAPK pathway and
cAMP response element-binding protein (CREB) phosphoryla-
tion.Moreover, in vitro studies have shown that E2 can up-regulate
the CREB-dependent expression of the AP-1 protein c-fos (FBJ
osteosarcoma oncogene) in addition to increasing the AP-1 bind-
ing ability of c-fos in rat white adipocytes. These observations
suggest a role for E2 in regulating non-genomic MAPK signal-
ing in addition to increasing transcription of ER targets (such as
uncoupling protein 2 – ucp2) in adipose (Dos Santos et al., 2002).
Taken together, E2 has been shown to play an important age-
dependent role in the development of obesity and the metabolic
syndrome. However, the direct target genes of estrogen and ERs
remain largely unknown, as are the mechanisms of E2 action. In
the future, a tissue-speciﬁc E2 or SERM might be an appropriate
basis for the development of therapeutic regimens for obesity.
E2 IN SKIN AND HAIR FOLLICLES AND AGING
The skin and their accessory appendages (e.g., hair follicles, nails,
and sweat glands) are derived from ectoderm during development
and form the outermost barrier of the mammalian body. The skin
plays an important barrier function against pathogens and other
external factors, such as UV light. The effects of E2 are particularly
obvious in the skin since a huge number of epidemiological stud-
ies have provided convincing evidence that E2 inhibits skin aging
by preventing skin wrinkling and promoting: skin thickness, col-
lagen content, and skin moisture (reviewed in Thornton, 2002;
Verdier-Sevrain et al., 2006). In addition, E2 has been shown to
play a supportive role in skin wound healing (reviewed in Emmer-
son and Hardman, 2011). The ﬁrst study proving an effect of E2
on skin showed an improvement of acne and eczema upon E2
treatment; oral contraceptives are still used for the treatment of
severe acne (Loeser, 1937; Arowojolu et al., 2009).
The effects of E2 in skin are facilitated by the ERs ERα and
ERβ, which are both expressed in keratinocytes, ﬁbroblasts, and
melanocytes (Jee et al., 1994; Hughes et al., 1997; Haczynski et al.,
2002). Moreover, the skin is not only a target for sexual hormones
but also produces and releases E2 by enzymatic conversion of
estrogen precursors (reviewed in Emmerson andHardman, 2011).
During UV light-induced photoaging the expression of sev-
eral matrix metalloproteinases (e.g., MMP1, MMP2, MMP3, and
MMP9) are upregulated leading to collagen degradation, accom-
panied by the down-regulation of the expression of type I and
III collagens (reviewed in Baumann, 2005). Consistently, ovx rats
exposed to UVB radiation show an increase in deep wrinkles,
decreased skin elasticity and advanced curling of dermal ﬁbers
compared to control animals (Tsukahara et al., 2001, 2004). Inter-
estingly, the skin-protective effect of E2 seems to depend on active
transforming growth factor-β1 (TGF-β1) signals, which implies a
crosstalk between these two pathways in collagen homeostasis of
the skin (Son et al., 2005).
Skin thickness has been demonstrated to positively correlate
with E2 levels. Although many studies suggest that ﬁbroblasts
are the main target of E2 in the skin, E2 also stimulates the
proliferation of keratinocytes. This effect is mediated by two dif-
ferent E2-dependent mechanisms: on the one hand E2 induces
the transcriptional upregulation of the cell cycle regulators cyclin
D1 (CCND1) and CCND2, which promotes proliferation. On the
other, E2 inhibits keratinocyte apoptosis by the induction of Bcl-2
gene expression (reviewed in Verdier-Sevrain et al., 2006).
E2 plays another important role in skin wound healing. The
inﬂammatory response to a wound is strongly regulated by growth
factors and cytokines (Shaw and Martin, 2009). Decelerated
wound healing is a critical indication in postmenopausal women
(Ashcroft et al., 1997). Aged females show a notably decreased
expression of TGF-β1 in skin ﬁbroblasts, which play an impor-
tant role in the wound healing process. In cultured ﬁbroblasts
obtained from postmenopausal women mRNA expression levels
of both ERα and ERβ were increased after E2 treatment for 24 h
(Surazynski et al., 2003). Furthermore, E2 increases the expression
of insulin-like growth factor 1 receptor (IGF1R), which inﬂuences
the collagen biosynthesis in these cells (Surazynski et al., 2003).
These data highlight the important role of estrogen in improving
wound healing in the elderly skin. In addition, not only E2 but
also the phytoestrogen genistein can modulate wound healing.
Treatment of ovx mice with genistein inhibits, like E2, the expres-
sion of pro-inﬂammatory cytokines, such as interleukin-6 (IL-6)
and tumor necrosis factor alpha (TNFα; Emmerson et al., 2010).
Consistently, Chung et al. (2000) found the cytokine target gene
and transcription factor c-jun to be upregulated in elderly Cau-
casian skin compared to young skin samples. Macrophage migra-
tion inhibitory factor (MIF) also contributes to the inﬂammatory
response in skin (Shimizu, 2005). In wounded ovx wildtype mice
an increase in Mif gene expression could be detected (Ashcroft
et al., 2003). Interestingly, in Mif-null mice E2 depletion had no
delayed effect on wound healing (Ashcroft et al., 2003). These data
suggest thatMIFmight be amediator of excessive inﬂammation in
the absence of E2. Therefore, the anti-inﬂammatory role of E2 via
down-regulation of MIF should be also considered as an impor-
tant effect in other disorders of postmenopausal women, such as
osteoporosis or atherosclerosis.
Hair follicles represent a unique skin appendage since they peri-
odically regenerate new hair during the hair cycle. E2 has been
shown to inhibit hair growth inmanymammalian species (Thorn-
ton, 2002). In contrast, in humans E2may have a stimulatory effect
on hair growth,most probably by shortening the resting phase and
prolonging the hair growth phase of the hair cycle (Sinclair et al.,
1999). Accordingly, treatments of females with the E2-antagonist
tamoxifen or with aromatase-inhibitors result in hair thinning or
recession (reviewed in Stevenson and Thornton, 2007). Recently,
a study has shown that E2 treatment for 6 h signiﬁcantly upregu-
lates the expression of PRL (prolactin) and its receptor PRLR in
the human hair follicle (Langan et al., 2010). These data provide
new insights into the extra-pituitary expression patterns of PRL
and PRLR and show that skin and hair follicles are both target and
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an extra-pituitary source of PRL, which vice versa also regulates
hair growth.
In summary, a number of studies have established an essen-
tial function of E2 in skin biology. Therefore, E2 may offer an
appropriate treatment option to prevent or delay age-associated
alterations of the skin by affecting dermal ﬁbroblasts, epidermal
keratinocytes, or hair follicles.
E2 IN THE BRAIN AND AGING
Several studies with estrogen replacement therapy have shown a
signiﬁcant effect of estrogens on brain biology (Craig andMurphy,
2007). These data raise the question if the loss of estrogens or the
decline in ER expression contributes to this phenomenon.
In animal studies an age-related reduction of ERα and ERβ
expression was observed in the female brain (Wilson et al., 2002;
Thakur and Sharma, 2007). Interestingly, the decline in ERs was
region speciﬁc when samples from cerebral cortex and hypothala-
muswere analyzed (Wilson et al., 2002;Thakur and Sharma,2007).
Studies with ERαKO, ERβKO, and double mutant ERαβKO mice
revealed a receptor subtype-speciﬁc action of E2 depending on
the brain area (Hill and Boon, 2009). In ovariectomized rats both
receptors, ERα and ERβ, are expressed with either overlapping
or region speciﬁc differences (Shughrue et al., 1997; Mohamed
and Abdel-Rahman, 2000; Shughrue and Merchenthaler, 2000;
Rose’Meyer et al., 2003). Both ERα and ERβ are regulated in
E2-depleted mice depending on the brain region (Mohamed and
Abdel-Rahman, 2000; Rose’Meyer et al., 2003).
The widely used model of ovariectomy to mimic depleted E2
levels has been used to investigate E2-dependent gene expression
patterns in the brain of rodents. The expression of the cytoprotec-
tive heat shock protein (Hsp) and subtypes of the neuroprotective
adenosine receptor (Adora) were decreased after ovariectomy sug-
gesting the involvement of E2 in these neuroprotective effects
(Rose’Meyer et al., 2003; Hou et al., 2010).
In the pituitary gland the role of E2 was analyzed by an in vitro
model that uses GH3 cells derived from a rat pituitary tumor
(Tashjian et al., 1968). In these cells a decrease in steroid receptor
coactivator-1 (Src-1) expression was shown after E2 treatment for
24 h,whereas nuclear receptor corepressor (NCoR)mRNA expres-
sion levels were not altered in the presence of E2 (Misiti et al.,
1998). In vivo studies with male rats receiving a single s.c. injec-
tion of E2 (5μg/kg body weight) have revealed time-dependent
changes in silencing mediators of retinoid and thyroid hormone
receptors (Src-1 and Smrt ) in the pituitary, but no effects in NCoR
or p300 expressionwere found (Misiti et al., 1998). These data sug-
gest an E2-speciﬁc modulation of transcriptional co-regulators in
thepituitary.However,only the expressionof transforming growth
factor beta isoforms was analyzed in normal pituitary and in rela-
tion to age (Hentges et al., 2000). E2-regulated genes in the normal
pituitary remain unknown.
During the last three decades it became clear that many severe
brain-related diseases can be linked with E2 function. The devel-
opment of Alzheimer’s disease (AD) might be estrogen-speciﬁc
due to the higher prevalence for women than men (Henderson,
2006). Furthermore, the incidence for AD in women increases
with age with a low risk at the age of 50 (Henderson, 2006). The
hypothesis that E2 replacement therapy reduces the risk of ADwas
conﬁrmed in several studies (Cutter et al., 2003; Brinton, 2005;
Henderson, 2006). However, these data are in contrast to the ﬁnd-
ings of the Women’s Health Initiative Memory Study (WHIMS;
reviewed in Candore et al., 2006; Henderson, 2006). In this study
the risk of dementia was highly increased for women that received
HRT (reviewed in Candore et al., 2006; Henderson, 2006). The
hippocampus,which belongs to the limbic system, is an important
brain structure for memory functions and might be an interest-
ing region to study the role of E2 in normal function and AD
(Eichenbaum et al., 1992). In postmenopausal women the expres-
sion of ERα was increased in hippocampal subareas (Ishunina
et al., 2007). Additionally, Ishunina et al. (2007) analyzed sam-
ples from female patients with AD that showed a down-regulation
of ERα and aromatase (CYP19A1) expression in the hippocam-
pus. Furthermore, in the human brain ERα splice variants were
found that changed with both age and AD progression (McEwen,
2001; Perlman et al., 2005; Ishunina et al., 2007; Ishunina and
Swaab, 2008). These results may imply that elderly women have an
increased risk for AD. The increasing amounts of data for AD and
related gene expression patterns are publicly available and contin-
uously updated in the AlzGene database (http://www.alzgene.org;
Bertram et al., 2007).
Apolipoprotein E (ApoE) is a major risk factor in AD due to its
high correlation with ApoE-4 allele in AD patients (Corder et al.,
1993; Poirier, 1996). In cerebrospinal ﬂuid of those patients a sig-
niﬁcant reduction of ApoE was observed (Blennow et al., 1994).
The underlying mechanism for the connection between ApoE and
AD is still unclear. One hypothesis suggests an impaired lipid
transport via ApoE in the brain of AD patients resulting in a loss
of plasticity and synaptic integrity (Poirier, 1996). Importantly,
several studies have demonstrated an E2-dependent increase of
ApoE expression in vitro and in vivo (Stone et al., 1997). Fur-
thermore, the expression of glial ﬁbrillary acidic protein (GFAP),
which modiﬁes astrocyte–neuron interactions, shows an estrus-
dependent variability and has been studied in more detail (Olmos
et al., 1989; Naftolin et al., 1996). After 24 h E2-treatment GFAP
was increased in ApoE-synthesizing astrocytes (Stone et al., 1998).
These data indicate that an E2-induced increase ofApoE andGFAP
may contribute to an improvement in lipid transport and cell–cell-
interactions in the brain and therefore suggests a neuroprotective
action of E2.
Cholinergic neurons from basal forebrain, medial septum, and
nucleus basalis magnocellularis innervate areas of the cortex and
hippocampus andmay be involved in learning andmemory, while
cognitive decline in AD is accompanied by reduced choline acetyl
transferase (Chat) activity and loss of these neurons (Luine et al.,
1986; Price, 1986). Neurotrophins, which include brain derived
nerve factor (BDNF) and nerve growth factor (NGF) are account-
able for the development andmaintenance of cholinergic neurons
and their signal transduction occurs via binding to tyrosine kinase
receptor type 1 (TRKA). In ovx rats expression of Chat and TRKA
in the basal forebrain and Bdnf and Ngf in the cortical and hip-
pocampal brain are reduced (Singh et al., 1993, 1995; McMillan
et al., 1996). Interestingly, the reduced expression of Chat and
TRKA in the medial septum and nucleus basalis magnocellularis
was only detectable 6months after ovariectomy, but not 3months
post-ovariectomy (Gibbs, 1998).
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Major signs for the manifestation of aging and age-associated
disorders like Parkinson’s and AD are the loss of neurotransmit-
ters and their receptors leading to the reduced responsiveness to
neurotransmitters (reviewed in Enna et al., 1987). Degradation of
the nigrostriatal dopaminergic pathway, a discrete brain region,
leads to impaired sensorimotoric control and is therefore charac-
teristic for Parkinson’s disease (PD; Gillies and McArthur, 2010).
The development of PD is associated with age and gender due to
its high prevalence over the age of 65 and the twofold higher risk
in men, respectively (Gillies and McArthur, 2010). Therefore, it
is not surprising that data from clinical studies show parkinson-
ian symptoms in postmenopausal women and a decline in risk
and development of PD with E2 replacement therapy (reviewed
in Gillies and McArthur, 2010). Concentrations of both striatal
dopamine receptors, D1 and D2, decrease with age (Roth, 1990).
These changes are associated with a reduced control in motor
function and may be more related to the D2 receptor (O’Boyle
and Waddington, 1984; Henry et al., 1986). Mesco et al. (1991)
observed a 56% reduced expression of Drd2 (dopamine receptor
D2) in old rats. Roth and Joseph (1994) suggested that admin-
istration of E2 to adult male or ovx female rats will lead to an
increase of striatal dopamine receptors. These results imply that
E2 or a SERM may be a suitable therapeutic for the treatment of
PD considering the role of estrogen in the dopaminergic system
(Roth and Joseph, 1994).
The process of normal aging coincides with a growth hormone
(GH) deﬁciency (Lamberts et al., 1997).Adults withGHdeﬁciency
have characteristic symptoms and signs, like increased abdominal
fat mass, depressed mood, or decrease in bone density, which are
some features similar to symptoms of postmenopausal women
(Lamberts et al., 1997; Carroll et al., 1998). The expression of Gh
shows sexual dimorphism in pituitary and hypothalamic sections
with higher mRNA levels in male rats and a decline during aging
(Takahashi et al., 1990;Martinoli et al., 1991; Iruthayanathan et al.,
2005). Treatment of pituitary cells with E2 for 24 h resulted in
an increase of Gh (Iruthayanathan et al., 2005). Remarkably, in
the hippocampus contrary results were observed regarding Gh
expressionwith higher levels in females thanmales and an increase
during age (Donahue et al., 2006). The stimulationof GHsecretion
occurs via GH releasing hormone (Ghrh), which is produced in
the hypothalamus, and expression of Ghrh is reduced in pituitary
with age in female rats (Iruthayanathan et al., 2005). Interest-
ingly, somatostatin (Sst ), which acts opposing to Ghrh, is also
reduced with age in female rats (Martinoli et al., 1991). These data
imply that age-related and therefore E2-dependent changes of Gh
expression are region speciﬁc in the brain.
Data from the Colorado Thyroid Study showed a higher preva-
lence for hypothyroidism in postmenopausal women (Canaris
et al., 2000). Thyrotropin-releasing hormone (TRH) is produced
in hypothalamus and stimulates the release of thyroid-stimulating
hormone in the pituitary. TRH is inactivated by TRH-degrading
enzyme (THRDE). When E2 (5μg/kg body weight) was s.c.
injected into male rats, Trhde expression was decreased in the
pituitary, whereas levels of Trhr mRNA were increased after 6 h
followed by normalization of gene expression after 24 h (Schom-
burg and Bauer, 1997). In contrast, the expression of Trhde and
Trhr was not altered in the hypothalamus after E2 administration
(Schomburg and Bauer, 1997). These results suggest an organ-
speciﬁc effect of E2 on gene expression and show that E2 may be
used as an appropriate therapeutic in age-related hypothyroidism.
Studies from Watters and Dorsa suggest a signal-crosstalk
between E2 and the cAMP signaling pathway in the brain.
They could show that ovariectomy leads to a reduction of neu-
rotensin/neuromedin (NT/N ) expression in the mouse brain.
Interestingly, this down-regulation is rapidly normalized 8 h after
i.p. administration of 50μg E2/kg body weight (Watters and
Dorsa, 1998). The fact that the neurotensin promoter contains
CREB recognition sites and that a single E2 dose given to ovx rats
increases the immunoreactivity of phosphorylated CREB in neu-
rons suggests a signal-crosstalk between the estrogen and cAMP
pathways (Kislauskis et al., 1988; Zhou et al., 1996). Another possi-
ble signaling cascade interacting with E2 was described by Cabilla
et al. (2006). Administration of 40μg E2/kg body weight resulted
in the regulation of NO-sensitive or soluble guanylyl cyclase sub-
unit alpha 1 (sGCα1) and sGCβ1 in ovx rats, which are receptors
of nitric oxide (NO) synthase implying that E2 may be involved in
the NO/sGC/cyclic GMP pathway.
Taken together, these data highlight both a region speciﬁc and
dose-dependent role of estrogen in the brain.Whilewe knowmany
genes regulated by E2 in the brain, it is still a challenge to cre-
ate the optimal treatment for postmenopausal women developing
brain-related diseases like AD or PD.
E2 IN SKELETAL MUSCLE AND AGING
Several studies have demonstrated that lower circulating E2 levels,
but not local E2 concentrations, are associated with loss in mus-
cle strength and muscle mass (Pollanen et al., 2011 and reviewed
in Lowe et al., 2010). This decrease in muscle can be prevented
by HRT in peri- and post-menopausal woman (reviewed in Lowe
et al., 2010). The beneﬁcial role of E2 for muscle strength has
been also veriﬁed in mouse models, where ovariectomy leads to
10–20% weaker muscles compared to normal or E2-treated mice
(Lowe et al., 2010). Increased muscle strength, in combination
with improvedmuscle composition (i.e., decreased fat, see above),
improves overall performance, including a decrease in falls in the
elderly (Sipila et al., 2001; Ronkainen et al., 2009). Long-term stud-
ies in postmenopausal women have suggested that HRT, alone
or in combination with power training, affects gene transcrip-
tion thereby regulating energy metabolism, contraction response,
andmitochondrial function of the skeletal muscle (Pollanen et al.,
2010; Ronkainen et al., 2010). It is also hypothesized that estro-
gens decrease oxidative damage in muscles (Lowe et al., 2010) and
affect myosin function (Moran et al., 2007). Furthermore, data
from animal studies suggest a gender and E2-speciﬁc inﬂuence on
membrane stability and exercise-induced muscle damage (Enns
and Tiidus, 2010).
Both estrogen receptors, ERα and ERβ, are expressed in skele-
tal muscles (Lemoine et al., 2003; Wiik et al., 2003, 2009a). E2
treatment of rat skeletal myotubes for 6 h enhances the mRNA
expression of ERβ but not ERα (Wiik et al., 2009b). In addition,
muscle contractions induced by electrostimulation were shown
to increase ERβ expression suggesting that E2 in combination
with exercising could inﬂuence skeletal muscle conditions (Wiik
et al., 2009a). A second study showed that after E2 treatment
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ERα mRNA but not ERβ levels were increased (Dieli-Conwright
et al., 2009). These conﬂicting studies in gene regulation of ERα
and ERβ suggest the need for functional studies, such as chro-
matin immunoprecipitation (ChIP), to determine the roles for
each receptor in skeletal muscle cells.
The skeletal muscle is an important site for insulin resistance
and notably ERα−/− mice show adipocyte hyperplasia and hyper-
trophy, glucose intolerance, and insulin resistance (Heine et al.,
2000). The latter is one symptom of the metabolic syndrome for
which postmenopausal women have a higher risk compared to
premenopausal women (see the above section on E2 in adipose
tissue and aging; Park et al., 2003). It has been demonstrated that
estrogen receptors play a subtype-speciﬁc role in muscle glucose
metabolism. The expression of insulin-regulated glucose trans-
porter GLUT4 is not affected by the loss of ERβ but is extremely
low in ERα knockout mice (Barros et al., 2006). These data sug-
gest a mechanism for the insulin resistance of ERα−/− mice and
illustrate the essential function of ERα for glucose homeostasis in
the skeletal muscle.
A study by Dieli-Conwright and colleagues investigated the
inﬂuence of E2, tamoxifen (TAM) and raloxifene (RAL) onmRNA
expression in human skeletal muscle cells. The expression of
important co-regulators of estrogen receptors in skeletal mus-
cle were ﬁrst examined, such as the steroid receptor co-activator
(SRC-1,NCOA1) and the silencing mediator for retinoid and thy-
roid hormone receptors (SMRT ). A signiﬁcant increase in SRC-1
and decrease in SMRT expression could be detected after 24 h
treatment with E2. These changes in co-regulators probably have
global effects in the response to E2, but was not investigated in
this cell type. This report also described the role of E2 and SERMs
on key muscle genes. The expression of MyoD, a stimulator for
myoblast differentiation, was increased after E2 treatment but not
after incubation with TAM or RAL. The expression of the insulin-
regulated glucose transporter GLUT4 was increased with E2 and
RAL, but decreased with TAM treatments (Dieli-Conwright et al.,
2009). These studies highlight the E2-responsive nature of skele-
tal muscle and the tissue-speciﬁc and gene-speciﬁc differences in
SERM action.
Further studies established the role of E2 in muscle develop-
ment,duringwhich differentiation and cell growth are reciprocally
exclusive events in the myogenic lineage. It was shown that E2
promotes MyoD expression and differentiation in mouse skeletal
muscle and dividing myoblasts. The release of the repressing AP-1
transcription factor from theMyoD promoter was identiﬁed as the
molecular mechanism (Pedraza-Alva et al., 2009). Furthermore,
hypertrophy of skeletal muscles is associated with an upregulation
of Four and a Half LIM domain 1 (Fhl1; Loughna et al., 2000) and
E2 down-regulates the expression of Fhl1 in rat myoblasts sug-
gesting a growth-inhibitory role (Wang et al., 2010). Kahlert et al.
(1997) showed that E2 could not stimulatemyoblast growth. Taken
together, these data suggest a role of E2 for the myogenic lineage
by favoring differentiation during muscle cell development.
Apoptosis of muscle normally occurs during development to
control the number of proliferating myoblasts. The protective role
of E2 inmurine skeletalmuscle cells has been also linked to an anti-
apoptotic effect (Vasconsuelo et al., 2008). This protective action
is mediated by non-genomic pathways involving PI3K/Akt. Both
ERα and ERβ were shown to be necessary for the activation of
AKT. Interestingly, ERβ had a greater anti-apoptotic effect at the
mitochondrial level (Vasconsuelo et al., 2008; Ronda et al., 2010).
In summary, E2 effects skeletal muscle differentiation and sur-
vival and we are just beginning to understand the gene regulation
by E2 in this cell type. Overall, E2 has beneﬁcial effects on skeletal
muscle and this combined with its effects on bone, leads to an
overall reduction in the risk of osteoporotic fractures. The clin-
ical effects of SERMs in skeletal muscle is only beginning to be
explored (Jacobsen et al., 2008).
E2 IN THE CARDIOVASCULAR SYSTEM AND AGING
Premenopausal women have a lower incidence of cardiovascular
disease than men, whereas there is no difference after menopause,
suggesting that estrogens may play a role. However the WHI
showed that treatment of postmenopausal women with estro-
gen plus progestin did not prevent cardiovascular disease. Two
additional trials – the Heart and Estrogen/Progestin Replacement
Study (HERS; Hulley et al., 1998) and the estrogen replacement
and atherosclerosis trial (ERA; Lakoski et al., 2005) also failed
to show the protective effects of HRT in the cardiovascular sys-
tem. The clinical implications of these studies are controversial
and it has been suggested that perhaps lower doses of hormones
and/or beginning HRT near the onset of menopause rather than
years afterward may reduce the risks of HRT (Rozenbaum, 2006).
Alternatively, estrogens may have protective effects earlier in life
and may not be able to be used to treat cardiovascular disease. In
contrast, data from a huge number of animal studies have demon-
strated a cardio-protective effect of E2 (reviewed in Arnal et al.,
2007; Deschamps et al., 2010).
Many of the effects of estrogens in the cardiovascular system
are on the lipid proﬁle. High serum lipid levels (especially LDL)
contribute to atherosclerosis. Estrogens lead to decreased LDL and
increased HDL. Tamoxifen and raloxifene also decrease LDL.
ERα and ERβ are both expressed in human and rat cardiac
myocytes and ﬁbroblasts. Studies have shown cardiac abnormal-
ities in ERαKO and ERβKO mice, such as polarization defects,
increased organ size and hypertension (Johnson et al., 1997; Zhu
et al., 2002; Forster et al., 2004). Polymorphisms in ERα and ERβ
are associated with increased risk of cardiovascular disease only
in women, further demonstrating the role of estrogen signaling in
the cardiovascular system. The rs2234693 single nucleotide poly-
morphism (SNP) is associated with signiﬁcantly increased risk
of myocardial infarction (MI) among postmenopausal women
(Shearman et al., 2006). This SNP is not in a coding region of
the ERα protein, and it is unknown how this SNP increases MI.
Methylation of the ERα promoter, and a subsequent reduction of
ERα protein, is also associated with cardiovascular disease (Post
et al., 1999).
E2 has a direct role in cardiac myocytes. Spontaneously
hypertensive rats that underwent ovariectomy showed increased
myocardial apoptosis accompanied by the upregulation of Bcl-2-
associated X protein (Bax), angiotensin converting enzyme (Ace),
angiotensin II type 1 receptor (At1), and brain natriuretic peptide
(Bnp), which demonstrates a protective effect of E2 on stressed
myocardial cells (Fabris et al., 2011). Treatment of myocardial
endothelial cells with E2 resulted in upregulation of Claudin 5
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(Cldn5), which is an important integral membrane tight junction
protein (Burek et al., 2010). These data show that E2, in addition
to protection against apoptosis, might have a protective effect on
the cytoskeletal integrity of cardiovascular cells.
Lipoprotein lipase (LPL) plays an important role in heart
energymetabolism and fatty acid uptake. E2 increases LPL expres-
sion in the mouse heart (Liu et al., 2008). LPL is increased after
2 h of E2 treatment, suggesting that LPL is a direct ER target. A
decrease in LPL can lead to decreased cardiac function, and thus
aftermenopause cardiovascular disease is in part regulated by LPL.
A 1 h treatment with E2 was shown to increase transcrip-
tion of adenine nucleotide translocator 1 (ANT1) in the heart of
ovariectomized female rats, but not in male rats (Too et al., 1999).
Alterations in ANT expression have been linked to cardiac disease.
Furthermore, knockout mice deﬁcient in ANT1 showed charac-
teristics of heart disease (Graham et al., 1997). Two other proteins
that show gender speciﬁc upregulation in the heart are connexin
43 and progesterone receptor; they have an increased induction
in female cardiac myocytes over that observed in male cardiac
myocytes (Grohe et al., 1997). The functional consequences of E2-
mediated upregulation of these two proteins in the heart are not
clear.
Estrogens regulate not only the heart, but also the vasculature.
ERα and ERβ are both expressed in vascular endothelial cells and
vascular smoothmuscle cells. E2 regulates many genes in these cell
types, such as adhesionmolecules and genes involved in angiogen-
esis, vascular remodeling, and inﬂammation (reviewed inKlouche,
2006). Down-regulation of these E2-regulated genes is associated
with atherosclerosis and other vascular diseases.
The protective effects in the vasculature are in part regulated by
an E2-mediated increase in vasodilation of atherosclerotic arteries.
E2 increases endothelial nitric oxide activity (eNOS), which is not
mediated by ER transcription, but a rapid ERα-dependent non-
genomic effect that occurs in as little as 5min after E2 treatment
(Chen et al., 1999). Interestingly, raloxifene, but not tamoxifen,
also increases eNOS activity (Simoncini and Genazzani, 2000).
Estrogen receptor beta knockout mice have sustained systolic
and diastolic hypertension (Zhu et al., 2002). Furthermore, vascu-
lar smoothmuscle cells from thesemice show abnormalities of ion
channel function. These phenotypes suggest a protective role for
ERβ in the cardiovascular system via the vasculature. Through
microarray analysis Otsuki et al. (2003) indentiﬁed lipocalin-
type prostaglandin D synthase (L-PGDS) as a direct target of
ERβ in the heart. L-PGDS acts to catalyze the isomerization of
prostaglandin H2, a common precursor of various prostanoids, to
produce prostaglandin D2 (PGD2). PGD2 can act as a vasodila-
tor and anticoagulant to protect the cardiovascular system. Fifteen
other E2-regulated genes in the heart were identiﬁed by this study.
In summary, estrogen targets both the vasculature and the
heart. While we know many genes regulated by E2 in the car-
diovascular system, the optimal treatment of humans with HRT
or SERMs still must be determined.
E2 AND HOT FLUSHES AND AGING
Hot ﬂushes are a major unfavorable symptom during menopause
that has been causally linked with different organs and tissues.
Data from clinical trials indicate that 40–87% of postmenopausal
womenhad experienceswith vasomotor symptoms like hot ﬂushes
(Hagstad and Janson,1986; Freedman,2005).Althoughhot ﬂushes
occur concurrently with the loss of estrogens, estrogen levels do
not correlate between women experiencing hot ﬂushes and those
not experiencing hot ﬂushes (Hutton et al., 1978). However, HRT
does alleviate hot ﬂushes (Nelson, 2004). The molecular role of
estrogens in the initiation of hot ﬂushes and the genes regulated
by E2 to prevent hot ﬂushes are unknown.
Interestingly, several datasets suggest an association of obesity
and the severity of hot ﬂushes in postmenopausal women (Chiechi
et al., 1997; Wilbur et al., 1998). In adipocytes of postmenopausal
women the potential vasodilator adrenomedullin (ADM ) was
found to be upregulated (Gupta et al., 2007; Li et al., 2007).
Furthermore, another vasodilator, calcitonin-gene-related peptide
(CGRP) is also regulated in adipose tissue of postmenopausal
women (Gupta et al., 2007). Unfortunately, no data about the body
mass index of the fat sample donors was given. These data suggest
a 17β-estradiol-dependent regulation of adipokines actions, either
directly or indirectly, which are possibly involved in hot ﬂushes of
postmenopausal women.
In clinical trials norepinephrine in combination with serotonin
was effective in the treatment of hot ﬂushes in postmenopausal
women (Hall et al., 2011). Furthermore, studies demonstrated
peripheral heat loss and vasodilation accompanied with decline in
body temperature after injection of norepinephrine into preoptic
hypothalamus (Freedman, 2005). The facts that norepinephrine
acts in part via a2-adrenergic receptor modulated by estrogens in
the brain and the central activity of norepinephrine is regulated
by gonadal steroids suggest a possible combination of agents in
the treatment of vasomotor symptoms in postmenopausal women
(Freedman, 2005).
Because of the cardiovascular events associated with HRT,
estrogens are no longer recommended for the treatment of hot
ﬂushes. No consistent results are obtained with phytoestrogens,
such as soy in the treatment of hot ﬂushes (Kronenberg and
Fugh-Berman, 2002). Furthermore, SERMs such as raloxifene and
tamoxifen do not alleviate hot ﬂushes (see Table 1). Therefore, an
“ideal” SERM needs to be developed to reduce the occurrence of
hot ﬂushes.
CONCLUSION
While estrogens and their physiological roles have been well-
characterized in breast, breast cancer, and in the female repro-
ductive tract, less is known about the direct targets of estrogens
in other tissues, such as bone, adipose tissue, skin, hair, brain,
skeletal muscle, and cardiovascular system. The WHI and other
clinical trials and observational data have illustrated that estro-
gens affect many tissues throughout the body. Moreover, when we
treat postmenopausal women with HRT or breast cancer patients
with anti-estrogens there are many desirable and undesirable con-
sequences. We must fully understand the molecular and cellular
effects of estrogens in each of these tissues to best treat women.
We are only just beginning to understand how tissue speci-
ﬁcity occurs on the molecular and transcriptional level. Of par-
ticular interest are ﬁndings on the functions of E2-interacting
transcription factors. For instance, FoxA1 is a well-characterized
“pioneer factor” for ERα in breast cancers, helping to recruit ERα
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to breast-speciﬁc enhancer regions (Carroll et al., 2005). How-
ever, FoxA1 is not expressed in all estrogen responsive tissues (for
example it is not expressed in bone cells; Krum et al., 2008b).
In addition, in osteoblasts, GATA4 is a pioneer factor for ERα
and helps recruit ERα to osteoblast-speciﬁc enhancers (Miranda-
Carboni et al., 2011). Yet, it is unknown how ERα is recruited to
enhancers in other tissues butmany other analogous examples will
most likely exist and remain to be identiﬁed. Each tissue may have
its own pioneer factor or there might be a small set of proteins
that in different combinations determine where ERα is recruited
in each cell type.
In parallel, tissue speciﬁcity is also determined in part by dif-
ferent coactivators expressed in each cell type. For example, the
coactivator SRC-1 is necessary for agonist activity of tamoxifen
in endometrial cells. In breast cancer cells SRC-1 is expressed
at a lower level than in endometrial cells where tamoxifen is
an ERα antagonist (Shang and Brown, 2002). Many more addi-
tional, unknown factors determine tissue speciﬁcity of the estro-
gen response. There are over 300 nuclear receptor coactivators
and corepressors (O’Malley, 2008), suggesting an extremely com-
plex mechanism of E2 tissue speciﬁcity and related effects during
menopause and aging.
With the large number of diseases that canbe potentially treated
with estrogen agonists or antagonists, ideally, SERMs can be devel-
oped with a high level of target tissue speciﬁcity to best treat
patients with minimal side effects (Table 1). But ﬁrst we must
understand the mechanism of estrogen action in each tissue.
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